Revolution Medicines Inc

NASDAQ:RVMDUnited States

Revolution Medicines, Inc. is a clinical-stage precision oncology company. It is focused on developing targeted therapies to inhibit frontier targets in renin angiotensin system (RAS)-addicted cancers. Its research and development (R&D) pipeline comprises RAS (ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors in development-stage candidates include RMC-6236, RMC-6291, and RMC-9805. The RAS Companion Inhibitors include RMC-4630, RMC-5552, RMC-5845, and RMC-6236. RMC-6236, its RAS MULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants. RMC-6291 is designed as a potent, oral and selective tri-complex inhibitor of KRAS G12C(ON). RMC-9805 is designed as a potent, oral and selective tri-complex inhibitor of KRAS G12D(ON).

Contact Information

Headquarters

700 Saginaw DrREDWOOD CITY, CA, United States 94063-4752

Phone

415-766-3638

Fax

302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer

Mark Goldsmith

Chief Financial Officer

Jack Anders

President - Research and Development

Steve Kelsey

Chief Operating Officer

Margaret Horn

Executive Vice President - Clinical Development

Xiaolin Wang